Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib after inadequate dupilumab response in moderate to severe atopic dermatitis
ChiCTR2200066260Phase 4Not yet recruiting
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of upadacitinib in atopic dermatitis (AD), sponsored by Shenzhen Second People's Hospital. Primary endpoint: Proportion of patients achieving EASI 75 and EASI 90. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
upadacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on ChiCTR2200066260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066260.